bioMerieux (OTCMKTS:BMXMF) Receives Average Recommendation of “Reduce” from Analysts

bioMerieux (OTCMKTS:BMXMF) has received an average rating of “Reduce” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company.

Several brokerages recently weighed in on BMXMF. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Morgan Stanley downgraded shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a report on Tuesday, April 28th. Finally, Piper Sandler began coverage on shares of bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company.

bioMerieux Stock Performance

BMXMF opened at $80.66 on Friday. bioMerieux has a one year low of $77.00 and a one year high of $152.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48. The stock’s fifty day moving average is $81.83 and its 200-day moving average is $101.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.